SEARCH

SEARCH BY CITATION

References

  • Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 26152622
  • Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8: 25052511
  • Basler M, Beck U, Kirk CJ, Groettrup M (2011) The antiviral immune response in mice devoid of immunoproteasome activity. J Immunol 187: 55485557
  • Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ (2010) Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 185: 634641
  • Basler M, Groettrup M (2007) No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes. Eur J Immunol 37: 896904
  • Basler M, Kirk CJ, Groettrup M (2013) The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol 25: 7480
  • Basler M, Lauer C, Beck U, Groettrup M (2009) The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 183: 61456150
  • Basler M, Moebius J, Elenich L, Groettrup M, Monaco JJ (2006) An altered T Cell repertoire in MECL-1-deficient mice. J Immunol 176: 66656672
  • Basler M, Youhnovski N, Van Den Broek M, Przybylski M, Groettrup M (2004) Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol 173: 39253934
  • Becher B, Segal BM (2011) T(H)17 cytokines in autoimmune neuro-inflammation. Curr Opin Immunol 23: 707712
  • Bennett MK, Kirk CJ (2008) Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel 11: 616625
  • Chen WS, Norbury CC, Cho YJ, Yewdell JW, Bennink JR (2001) Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med 193: 13191326
  • Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, Suter T, Becher B (2011) RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12: 560567
  • Croxford AL, Kurschus FC, Waisman A (2011) Mouse models for multiple sclerosis: historical facts and future implications. Biochim Biophys Acta 1812: 177183
  • Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL, Magdelenat H (1998) The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 77: 11031107
  • El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, Zhang GX, Dittel BN, Rostami A (2011) The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12: 568575
  • Fehling HJ, Swat W, Laplace C, Kuehn R, Rajewsky K, Mueller U, von Boehmer H (1994) MHC class I expression in mice lacking proteasome subunit LMP-7. Science 265: 12341237
  • Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, Driessen C, Weissert R (2008) Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol 38: 24012411
  • Fitzpatrick LR, Khare V, Small JS, Koltun WA (2006) Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice. Dig Dis Sci 51: 12691276
  • Frausto RF, Crocker SJ, Eam B, Whitmire JK, Whitton JL (2007) Myelin oligodendrocyte glycoprotein peptide-induced experimental allergic encephalomyelitis and T cell responses are unaffected by immunoproteasome deficiency. J Neuroimmunol 192: 124133
  • Fuller KG, Olson JK, Howard LM, Croxford JL, Miller SD (2004) Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease. Methods Mol Med 102: 339361
  • Groettrup M, Kirk CJ, Basler M (2010) Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 10: 7378
  • Groettrup M, Ruppert T, Kuehn L, Seeger M, Standera S, Koszinowski U, Kloetzel PM (1995) The interferon-γ-inducible 11S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro. J Biol Chem 270: 2380823815
  • Groll M, Berkers CR, Ploegh HL, Ovaa H (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14: 451456
  • Hensley SE, Zanker D, Dolan BP, David A, Hickman HD, Embry AC, Skon CN, Grebe KM, Griffin TA, Chen W et al (2010) Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses. J Immunol 184: 41154122
  • Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, Kim KB (2007) LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol 14: 419430
  • Hosseini H, Andre P, Lefevre N, Viala L, Walzer T, Peschanski M, Lotteau V (2001) Protection against experimental autoimmune encephalomyelitis by a proteasome modulator. J Neuroimmunol 118: 233244
  • Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M, Groll M (2012) Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148: 727738
  • Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ et al (2012) Novel proteasome inhibitors have a beneficial effect in murine lupus via the dual inhibition of type i interferon and autoantibody secreting cells. Arthritis Rheum 64: 493503
  • Kalim KW, Basler M, Kirk CJ, Groettrup M (2012) Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T Cell differentiation. J Immunol 189: 41824193
  • Kincaid EZ, Che JW, York I, Escobar H, Reyes-Vargas E, Delgado JC, Welsh RM, Karow ML, Murphy AJ, Valenzuela DM et al (2012) Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol 13: 129135
  • Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ (2009) Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113: 46674676
  • Lassmann H (2005) Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol 15: 217222
  • Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J et al (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8: 500508
  • McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD (1992) Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 38: 229240
  • Moebius J, van den Broek M, Groettrup M, Basler M (2010) Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur J Immunol 40: 34393449
  • Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J et al (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15: 781787
  • Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, Goldberg AL (2013) Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152: 11841194
  • Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA et al (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14: 748755
  • Orlowski RZ, Eswara JR, LafondWalker A, Grever MR, Orlowski M, Dang CV (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58: 43424348
  • Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS et al (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol, 20: 44204427.
  • Petermann F, Korn T (2011) Cytokines and effector T cell subsets causing autoimmune CNS disease. FEBS Lett 585: 37473757
  • Peters J-M, Franke WW, Kleinschmidt JA (1994) Distinct 19 S and 20S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J Biol Chem 269: 77097718
  • Poppensieker K, Otte DM, Schurmann B, Limmer A, Dresing P, Drews E, Schumak B, Klotz L, Raasch J, Mildner A et al (2012) CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells. Proc Natl Acad Sci U S A 109: 38973902
  • Rockwell CE, Monaco JJ, Qureshi N (2012) A critical role for the inducible proteasomal subunits LMP7 and MECL1 in cytokine production by activated murine splenocytes. Pharmacology 89: 117126
  • Rosati G (2001) The prevalence of multiple sclerosis in the world: an update. Neurol Sci 22: 117139
  • Schmidt N, Gonzalez E, Visekruna A, Kuhl AA, Loddenkemper C, Mollenkopf H, Kaufmann SH, Steinhoff U, Joeris T (2010) Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 59: 896906
  • Schwarz K, van den Broek M, Kostka S, Kraft R, Soza A, Schmidtke G, Kloetzel PM, Groettrup M (2000) Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1 but not PA28α/β enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J Immunol 165: 768778
  • Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schroter F, Prozorovski T, Lange N, Steffen J, Rieger M et al (2010) Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142: 613624
  • Sijts AJAM, Standera S, Toes REM, Ruppert T, Beekman NJCM, vanVeelen PA, Ossendorp FA, Melief CJM, Kloetzel PM (2000) MHC class I antigen processing of an Adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. J Immunol 164: 45004506
  • Singh AV, Bandi M, Aujay MA, Kirk CJ, Hark DE, Raje N, Chauhan D, Anderson KC (2011) PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 152: 155163
  • Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23: 683747
  • Steinman L (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13: 139145
  • Toes REM, Nussbaum AK, Degermann S, Schirle M, Emmerich NPN, Kraft M, Laplace C, Zwinderman A, Dick TP, Muller J et al (2001) Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 194: 112
  • Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172: 146155
  • Van Kaer L, Ashton-Rickardt PG, Eichelberger M, Gaczynska M, Nagashima K, Rock KL, Goldberg AL, Doherty PC, Tonegawa S (1994) Altered peptidase and viral-specific T cell response in LMP 2 mutant mice. Immunity 1: 533541
  • Van Swieten PF, Samuel E, Hernandez RO, van den Nieuwendijk AM, Leeuwenburgh MA, van der Marel GA, Kessler BM, Overkleeft HS, Kisselev AF (2007) A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. Bioorg Med Chem Lett 17: 34023405
  • Vanderlugt CL, Rahbe SM, Elliott PJ, DalCanto MC, Miller SD (2000) Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 14: 205211
  • Whitehouse DJ, Whitehouse MW, Pearson CM (1969) Passive transfer of adjuvant-induced arthritis and allergic encephalomyelitis in rats using thoracic duct lymphocytes. Nature 224: 1322